Recent Medical News
13 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Dae Jang Geum
Scoop.it!

Targeted Delivery of Vascular Therapeutics

The Wyss Institute has developed a targeted vascular nanotherapeutic (Vascular NanoRx) platform that targets drugs to stenotic (narrowed) sites in blood vess...
more...
No comment yet.
Rescooped by Dae Jang Geum from Alzheimer’s: Advances-Knowledge, integrative, holistic treatments
Scoop.it!

Cannabis reverses late-stage Alzheimer's

Cannabis reverses late-stage Alzheimer's | Recent Medical News | Scoop.it
Cannabis reverses late-stage Alzheimer's

Via Troy Mccomas (troy48), 27Alzheimer’s
more...
No comment yet.
Rescooped by Dae Jang Geum from Cancer Immunotherapy Review
Scoop.it!

Astra Zeneca Imprint in Immuno-Oncology

Astra Zeneca Imprint in                Immuno-Oncology | Recent Medical News | Scoop.it

Immuno-oncology
Significant advancement has been made in the immuno-oncology portfolio since the pipeline update at Q1
results presentation on 24 April 2014, including:


 First patient randomisation in the Phase III PACIFIC study, investigating the efficacy of MEDI4736 as a
sequential therapy following chemoradiation in patients with locally advanced, unresectable NSCLC.


 At the American Society of Clinical Oncology (ASCO) meeting, AstraZeneca announced the Phase III investment decision made to investigate the combination of PD-L1 and tremelimumab in 3rd line
NSCLC patients to start in 2014. Subsequently, the Company has made the decision to initiate a pivotal programme for PD-L1
monotherapy as well as the combination with tremelimumab in head and neck cancer in 2014.


 The ongoing randomised study with tremelimumab in unresectable pleural or peritoneal mesothelioma has been expanded for registrational intent.


 Additional Phase I combination studies for MEDI4736 have been initiated, including combinations with Iressa and MEDI0680 (anti-PD-1 mAb). Other combination trials, including two Phase I studies in combination with AZD9291 are planned to start imminently.


The Company has also signed agreements to evaluate MEDI4736 in combination with Incyte’s IDO1 inhibitor, Kyowa Hakko Kirin’s anti-CCR4 antibody, mogamulizumab, and Advaxis’ lead cancer
immunotherapy, ADXS-HPV.

 

European Society for Medical Oncology (ESMO) meeting, 26 – 30 September 2014
AstraZeneca has submitted numerous scientific abstracts across its oncology pipeline for presentation at the
ESMO meeting in Madrid. The Company will also host a briefing for analysts and investors during the ESMO
conference, with anticipated highlights:
 Further update on PD-L1 monotherapy Phase I study.
 Update on PD-L1/CTLA-4 combination in NSCLC to include: More patients, further dosing cohorts and
PD-L1 biomarker status.
 Update on AZD9291 in NSCLC,

 

2Q2014 Results

 

AstraZeneca PLC second quarter and half year results 201431 July 2014


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, July 31, 2014 6:57 AM

Astra Zeneca has joined the immuno oncology bandwagon and is in race to catch up with leaders like BMS, Merck and Roche. BMS dominates and is the current market leader.

Rescooped by Dae Jang Geum from Cancer - Advances, Knowledge, Integrative & Holistic Treatments
Scoop.it!

Using the Body’s Own Immune System as a Cancer Therapy

Using the Body’s Own Immune System as a Cancer Therapy | Recent Medical News | Scoop.it
Increasingly, doctors are using their patients' own immune systems as valuable weapons against the disease.

Via Graham Player Ph.D.
more...
Graham Player Ph.D.'s curator insight, July 31, 2014 11:21 AM

The focus of cancer research has been on exploring ways to treat the tumor. It is always enlightening to see research that focuses on treating the patient rather than only the tumor.

Scientists have long tried to understand how to get the immune system—the body’s natural defense mechanism—to recognize cancer cells as the enemy, and destroy them. This has led to the introduction of immunotherapy, which induces, enhances, or suppresses an immune system response to help treat the disease condition. Its focus is on using the body’s own immune system. In terms of cancer this is an interesting and growing area of study.

Cancer immunotherapy is used to provoke the immune system into attacking the tumor cells. Cancer cells have subtly different molecules on their surface that can be detected by the immune system. The focus of immunotherapy in treating cancer is based on cell-based therapies, antibody therapies, and cytokine therapies.

Oncologist Dr. David Maloney is one of the oncologists on the forefront of the next major advance in immunotherapy. He infuses lymphoma patients with their own T-cells, re-engineered to produce a chimeric antigen receptor (or CAR T-cells) that, once triggered, can eliminate cancer. Unlike antibodies, which are broken down by the body over time, CAR T-cells may continue to multiply, serving as a “living therapy” throughout a patient’s life— staying on guard for any subsequent relapses.

Tambre Leighn's curator insight, August 1, 2014 12:11 PM

Breakthroughs like this are fantastic news...however, I would like to see just as much, if not more, emphasis on prevention.  There are many lifestyle choices that studies show impact the immune system as well as studies that indicate many medical professionals are not comfortable dealing with obesity and other issues that lead to chronic illness.  If people can experience greater quality of life and a much lower cost than going through chronic illness, we need to start giving medical professionals the training they need to communicate with their patients.  For more information, go to www.iPECwellbeing.com

Scooped by Dae Jang Geum
Scoop.it!

Science Nation - Nanosponge decoy fights superbug infections

Our first instinct with infection in the body is often to find it and get rid of it! But, engineer Liangfang Zhang had another idea. With support from the Na...
more...
No comment yet.
Scooped by Dae Jang Geum
Scoop.it!

HarvardX Fundamentals of Clinical Trials HMS214x About Video

This course will provide an introduction to the scientific, statistical, and ethical aspects of clinical trials research. Topics include the design, implemen...
more...
No comment yet.
Rescooped by Dae Jang Geum from Diabetes: Advances-Knowledge, integrative, holistic treatments
Scoop.it!

Researchers Discover Diabetes 'On-Off Switch'

Researchers Discover Diabetes 'On-Off Switch' | Recent Medical News | Scoop.it
Researchers Discover Diabetes 'On-Off Switch'
Newsmax Health
...

Via 27-Diabetes
more...
No comment yet.
Rescooped by Dae Jang Geum from Hepatitis C New Drugs Review
Scoop.it!

Why So Few Hepatitis C Patients Get Access to "Miracle Drug ...

Why So Few Hepatitis C Patients Get Access to "Miracle Drug ... | Recent Medical News | Scoop.it
The most crushing stat from a report out today by Public Health England is that, against a fanfare for new, improved, and in some cases near-“miracle” treatments, the number of those chronically infected with hepatitis C that ...

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, July 31, 2014 5:55 AM

The high cost of new HCV drugs 

Rescooped by Dae Jang Geum from diabetes and more
Scoop.it!

A new way to generate insulin-producing cells in Type 1 diabetes

A new way to generate insulin-producing cells in Type 1 diabetes | Recent Medical News | Scoop.it
Researchers discover a simple peptide that can induce new beta-cell formation in the pancreas. The findings show promise for a new approach to treating Type 1 diabetes.

Via Ellen H Ullman, MSW
more...
No comment yet.
Rescooped by Dae Jang Geum from The future of medicine and health
Scoop.it!

New microchip promises to streamline and simplify diabetes diagnoses

New microchip promises to streamline and simplify diabetes diagnoses | Recent Medical News | Scoop.it

For people who don't already know, here's the difference between type 1 and type 2 diabetes: the body produces little or no insulin in the case of type 1, and isn't able to utilize the insulin that it does produce in type 2. It's a significant difference, so it's important that patients are diagnosed correctly. Thanks to a new microchip developed by a team at Stanford University led by Dr. Brian Feldman, doing so could soon be quicker, cheaper and easier than ever before.

In order to determine that a patient has type 1 diabetes as opposed to type 2, tests must be performed to confirm the presence of tell-tale antibodies in a sample of their blood. These tests must be performed by extensively-trained personnel in a lab, they involve the use of radioactive materials, take days to get results, and cost hundreds of dollars per test.

Because of these factors, the tests are sometimes not even performed, as it's generally assumed that children will get type 1 and adults will get type 2. In recent years, however, childhood obesity has caused a rise in the number of kids getting type 2, plus there's also a puzzling increase in adults with type 1.

That's where the Stanford chip comes in.

It can be incorporated into a hand-held device that could be used in the field with minimal training, delivering results in minutes. The chip doesn't require any radioactive material, is worth about $20, and can be used for about 15 tests before needing to be replaced. Additionally, it only requires a drop of blood, as opposed to the larger amount needed in the traditional system.


Via Wildcat2030
more...
No comment yet.
Scooped by Dae Jang Geum
Scoop.it!

Lee Cronin: Print your own medicine

Chemist Lee Cronin is working on a 3D printer that, instead of objects, is able to print molecules. An exciting potential long-term application: printing you...
more...
No comment yet.